Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.
Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.
复制标题
心脏肿瘤学中的心脏磁共振：优点、权宜之计的重要性以及进行预授权的注意事项。
DOI：
10.1016/j.jaccao.2021.04.011
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Arnold A
中科院分区：
文献类型：
--
作者：
O'Quinn R;Ferrari VA;Daly R;Hundley G;Baldassarre LA;Han Y;Barac A;Arnold A
随着心脏肿瘤学的范围呈指数增长，无论是受影响的人数还是治疗的类型，癌症治疗的急性和晚期心脏毒性的诊断都变得越来越重要。与其他成像方式相比，心脏磁共振（CMR）是一种可以提供无与伦比的诊断信息的工具，但由于需要保险预授权，它的使用往往被推迟，以牺牲患者护理为代价。本文强调了CMR作为诊断方式的首选情况，并提供了更有可能被保险公司批准的诊断示例。它还提供特定的心脏肿瘤学诊断或问题，以帮助临床心脏肿瘤学家导航预授权过程。不断发展的癌症治疗方法提高了患者的生存率，但可能导致心脏毒性。CMR可以帮助诊断、预测，并为指导心脏毒性的管理提供见解。保险公司使用的CMR预授权通常会导致患者护理的相应延迟。对保险支付者和提供者进行宣传和教育对于克服这些障碍至关重要。
Diagnosis of acute and late cardiotoxicity from cancer therapeutics has become increasingly important as the scope of cardio-oncology increases exponentially, both in terms of the number of people affected and the types of therapies it encompasses. Cardiac magnetic resonance (CMR) is a tool that can offer unparalleled diagnostic information compared with other imaging modalities, but its utilization is often delayed, at the expense of patient care, due to the need for insurance pre-authorization. This paper highlights situations in which CMR is preferred as the diagnostic modality and provides examples of diagnoses more likely to be approved by insurance companies. It also provides specific cardio-oncology diagnoses or questions to help the clinical cardio-oncologist navigate the pre-authorization process. Evolving therapies for cancer improve patient survival but can result in cardiotoxicity. CMR can help diagnose, prognosticate, and offer insight to guide the management of cardiotoxicity. Pre-authorization for CMR, used by insurance companies, often leads to consequential delays in patient care. Advocacy and education of insurance payers and providers are essential to overcome these obstacles.
登录
查看更多内容
影响因子：
3.5
作者：
Haslbauer, Jasmin D.;Lindner, Sarah;Puntmann, Valentina O.
通讯作者：
Puntmann, Valentina O.
DOI：
10.1161/circimaging.115.004325
发表时间：
2016-08
期刊：
Circulation. Cardiovascular imaging
影响因子：
--
作者：
Jordan JH;Vasu S;Morgan TM;D'Agostino RB Jr;Meléndez GC;Hamilton CA;Arai AE;Liu S;Liu CY;Lima JA;Bluemke DA;Burke GL;Hundley WG
通讯作者：
Hundley WG
DOI：
10.1016/j.jcmg.2018.06.004
发表时间：
2018-08
期刊：
JACC. Cardiovascular imaging
影响因子：
--
作者：
Jordan JH;Todd RM;Vasu S;Hundley WG
通讯作者：
Hundley WG
影响因子：
37.8
作者：
Henson KE;Reulen RC;Winter DL;Bright CJ;Fidler MM;Frobisher C;Guha J;Wong KF;Kelly J;Edgar AB;McCabe MG;Whelan J;Cutter DJ;Darby SC;Hawkins MM
通讯作者：
Hawkins MM
影响因子：
45.3
作者：
Armenian, Saro H.;Lacchetti, Christina;Lenihan, Daniel
通讯作者：
Lenihan, Daniel